Literature DB >> 15140405

Regulation of microtubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarray.

Yiwei Li1, Xingli Li, Maha Hussain, Fazlul H Sarkar.   

Abstract

Taxotere showed antitumor activity against solid tumors including prostate cancer. However, the molecular mechanism(s) of action of Taxotere has not been fully elucidated. In order to establish such molecular mechanism(s) in both hormone-insensitive (PC3) and hormone-sensitive (LNCaP) prostate cancer cells, comprehensive gene expression profiles were obtained by Affymetrix Human Genome U133A Array. The RNA from the cells treated with 2 nM Taxotere was subjected to microarray analysis. We found that a total of 166, 365, and 1785 genes showed greater than two-fold change in PC3 cells after 6, 36, and 72 hours of treatment, respectively compared to 57, 823, and 964 genes in LNCaP cells. The expression of tubulin was decreased, whereas the expression of microtubule-associated proteins was increased in Taxotere-treated prostate cancer cells, confirming the microtubule-targeting effect of Taxotere. Clustering analysis showed downregulation of some genes for cell proliferation and cell cycle. In contrast, Taxotere upregulated some genes that are related to induction of apoptosis and cell cycle arrest. From these results, we conclude that Taxotere caused alterations of a large number of genes, many of which may contribute to the molecular mechanism(s) by which Taxotere affects prostate cancer cells. Further molecular studies are needed in order to determine the cause and effect relationships between these genes altered by Taxotere. Nevertheless, our results could be further exploited for devising strategies to optimize therapeutic effects of Taxotere for the treatment of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15140405      PMCID: PMC1502084          DOI: 10.1593/neo.03391

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  39 in total

Review 1.  Tubulin and microtubule structure.

Authors:  K H Downing; E Nogales
Journal:  Curr Opin Cell Biol       Date:  1998-02       Impact factor: 8.382

2.  The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines.

Authors:  I H Still; P Vince; J K Cowell
Journal:  Genomics       Date:  1999-06-01       Impact factor: 5.736

3.  Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers.

Authors:  Y Miyoshi; K Iwao; C Egawa; S Noguchi
Journal:  Int J Cancer       Date:  2001-05-01       Impact factor: 7.396

4.  Bcl2 is the guardian of microtubule integrity.

Authors:  S Haldar; A Basu; C M Croce
Journal:  Cancer Res       Date:  1997-01-15       Impact factor: 12.701

Review 5.  Mechanisms of action of taxanes in prostate cancer.

Authors:  C A Stein
Journal:  Semin Oncol       Date:  1999-10       Impact factor: 4.929

6.  Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells.

Authors:  V I Avramis; P Nandy; R Kwock; M M Solorzano; S K Mukherjee; P Danenberg; L J Cohen
Journal:  Anticancer Res       Date:  1998 Jul-Aug       Impact factor: 2.480

7.  Cluster analysis and display of genome-wide expression patterns.

Authors:  M B Eisen; P T Spellman; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

8.  The distribution of murine 115-kDa epithelial microtubule-associated protein (E-MAP-115) during embryogenesis and in adult organs suggests a role in epithelial polarization and differentiation.

Authors:  N Fabre-Jonca; J M Allaman; G Radlgruber; P Meda; J Z Kiss; L E French; D Masson
Journal:  Differentiation       Date:  1998-08       Impact factor: 3.880

9.  Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues.

Authors:  W S el-Deiry; T Tokino; T Waldman; J D Oliner; V E Velculescu; M Burrell; D E Hill; E Healy; J L Rees; S R Hamilton
Journal:  Cancer Res       Date:  1995-07-01       Impact factor: 12.701

Review 10.  Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer.

Authors:  B Fulton; C M Spencer
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

View more
  19 in total

Review 1.  A review of the past, present, and future directions of neoplasia.

Authors:  Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

2.  Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.

Authors:  Niranjan Awasthi; Changhua Zhang; Anna M Schwarz; Stefan Hinz; Margaret A Schwarz; Roderich E Schwarz
Journal:  Mol Cancer Ther       Date:  2014-03-07       Impact factor: 6.261

3.  CXCL12γ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes.

Authors:  Younghun Jung; Frank C Cackowski; Kenji Yumoto; Ann M Decker; Jingcheng Wang; Jin Koo Kim; Eunsohl Lee; Yugang Wang; Jae-Seung Chung; Amy M Gursky; Paul H Krebsbach; Kenneth J Pienta; Todd M Morgan; Russell S Taichman
Journal:  Cancer Res       Date:  2018-02-05       Impact factor: 12.701

4.  Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G1 Arrest/S Phase Delay and Inhibition of Apoptosis During Chemotherapy in Bone Marrow.

Authors:  Eunsohl Lee; Ann M Decker; Frank C Cackowski; Lulia A Kana; Kenji Yumoto; Younghun Jung; Jingcheng Wang; Laura Buttitta; Todd M Morgan; Russell S Taichman
Journal:  J Cell Biochem       Date:  2016-09-26       Impact factor: 4.429

5.  Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines.

Authors:  Umut Varol; Mustafa Degirmenci; Burcak Karaca; Harika Atmaca; Asli Kisim; Selim Uzunoglu; Canfeza Sezgin; Ulus Ali Sanli; Ruchan Uslu
Journal:  Tumour Biol       Date:  2014-10-09

6.  Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.

Authors:  Renée de Leeuw; Lisa D Berman-Booty; Matthew J Schiewer; Stephen J Ciment; Robert B Den; Adam P Dicker; William K Kelly; Edouard J Trabulsi; Costas D Lallas; Leonard G Gomella; Karen E Knudsen
Journal:  Clin Cancer Res       Date:  2015-02-15       Impact factor: 12.531

7.  [11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model.

Authors:  Bernd J Krause; Michael Souvatzoglou; Ken Herrmann; Axel W Weber; Tibor Schuster; Andreas K Buck; Roman Nawroth; Gregor Weirich; Uwe Treiber; Hans-Jürgen Wester; Sibylle I Ziegler; Reingard Senekowitsch-Schmidtke; Markus Schwaiger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-30       Impact factor: 9.236

8.  Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination.

Authors:  Ercument Cengiz; Burcak Karaca; Yuksel Kucukzeybek; Gurbuz Gorumlu; Mustafa K Gul; Cigdem Erten; Harika Atmaca; Selim Uzunoglu; Bulent Karabulut; Ulus A Sanli; Ruchan Uslu
Journal:  Mol Biol Rep       Date:  2009-03-14       Impact factor: 2.316

9.  Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment.

Authors:  Sebastian A Müller; Korbinian Holzapfel; Christof Seidl; Uwe Treiber; Bernd J Krause; Reingard Senekowitsch-Schmidtke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-08       Impact factor: 9.236

10.  Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.

Authors:  Niranjan Awasthi; Changhua Zhang; Anna M Schwarz; Stefan Hinz; Changguang Wang; Noelle S Williams; Margaret A Schwarz; Roderich E Schwarz
Journal:  Carcinogenesis       Date:  2013-06-26       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.